Can-Fite BioPharma American Depositary Shares
CANF
12 hedge funds and large institutions have $465K invested in Can-Fite BioPharma American Depositary Shares in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and 3 closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
2% less capital invested
Capital invested by funds: $472K → $465K (-$7.59K)
8% less funds holding
Funds holding: 13 → 12 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$54.1K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$44.7K |
| 3 |
Morgan Stanley
New York
|
+$32.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$384 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$14K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $311K | +$32.6K | +170 | +11% |
|
|
VF
2
Virtu Financial
New York
| $52K | +$54.1K | +282 | New |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $43K | +$44.7K | +233 | New |
|
4
Fifth Third Bancorp
Cincinnati,
Ohio
| $28K | – | – | – |
|
5
Stifel Financial
St. Louis,
Missouri
| $11K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $7K | +$384 | +2 | +6% |
|
7
Citigroup
New York
| $5K | – | – | – |
|
8
National Bank of Canada
Montreal,
Quebec, Canada
| $5K | – | – | – |
|
|
APA
9
American Portfolios Advisors
Holbrook,
New York
| $1.01K | – | – | – |
|
10
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $1K | – | – | – |
|
|
FDCDDQ
11
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $490 | – | – | – |
|
|
TWC
12
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $233 | – | – | – |
|
|
13
Citadel Advisors
Miami,
Florida
| – | -$14K | -57 | Closed |
|
|
14
Wells Fargo
San Francisco,
California
| – | -$2K | -8 | Closed |
|
CANF Hedge Fund Activity: Q2 2022 in Review
12 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q2 2022, worth a combined $465K — down 1.6% from $472K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CANF and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $54.1K. The largest seller was Citadel Advisors, exiting entirely with an estimated $14K sold.
- 12 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q2 2022, down from 13 in Q1 2022.
- Funds reported $465K of Can-Fite BioPharma American Depositary Shares stock for Q2 2022, down 1.6% quarter-over-quarter.
- 2 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q2 2022 and 3 closed out, a net change of -1 holder.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q2 2022 was Virtu Financial, an estimated $54.1K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q2 2022 was Citadel Advisors, an estimated $14K sold.
Based on aggregated 13F filings for Q2 2022.